ORLANDO (EGMN) - Despite promising early results, the addition of bevacizumab to interferon failed to translate into a survival advantage over interferon alone in the initial treatment of metastatic kidney cancer, according to data from two major trials presented at the annual meeting of the American Society of Clinical Oncology.Final results from the phase III, double-blind, 649-patient AVOREN trial showed a median overall survival of 23.3 months with bevacizumab (Avastin) plus interferon-alfa,...